Empagliflozin vs Nivolumab
Empagliflozin vs Nivolumab: Overview
This comparison examines the pharmacological differences between Empagliflozin and Nivolumab.
Mechanism of Action
Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Empagliflozin — 12.4 hours; Nivolumab — 27 days.
Chemical Properties
Molecular Formula: Empagliflozin — C23H27ClO7.
Molecular Weight: Empagliflozin — 450.9100 g/mol.
Type: Empagliflozin — Small molecule; Nivolumab — Antibody.